Back to School: How biopharma can reboot drug development. Access exclusive analysis here
GENZ reported second quarter EPS of $0.34, which beat by $0.02 the consensus estimate and was up from $0.25
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury